计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P127989-5mg |
5mg |
现货 ![]() |
| |
| P127989-10mg |
10mg |
现货 ![]() |
| |
| P127989-50mg |
50mg |
现货 ![]() |
|
| 英文别名 | N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide | s2421 | HY-14376 | N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide | PF04457845 | PF-04457845 | AC-36 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | PF-04457845 |
| 生化机理 | 强效和选择性不可逆的FAAH抑制剂(IC50 = 7.2 nM)。对FAAH的选择性高于其他丝氨酸水解酶。在大鼠炎性疼痛模型中显示功效。口服生物有效性和脑渗透性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 安乃近酰胺水解酶抑制剂 |
| 产品介绍 |
PF-04457845是FAAH选择性抑制剂,IC50为7.2 nM,具有镇痛和抗炎活性。 PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen. |
| 纯度 | ≥98% |
| ALogP | 3.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide |
| INCHI | 1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32) |
| InChi Key | BATCTBJIJJEPHM-UHFFFAOYSA-N |
| Smiles | C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4 |
| Isomeric SMILES | C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4 |
| 分子量 | 455.43 |
| Reaxy-Rn | 18295423 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=18295423&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 45.54, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 9.11, 最高浓度(mM): 20 |
|---|---|
| 分子量 | 455.400 g/mol |
| XLogP3 | 3.300 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 455.157 Da |
| 单同位素质量Monoisotopic Mass | 455.157 Da |
| 拓扑极表面积Topological Polar Surface Area | 80.200 Ų |
| 重原子数Heavy Atom Count | 33 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 679.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| WGK Germany | 3 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | P127989 |
| 1. Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT et al.. (2011) Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.. ACS Med Chem Lett, 2 (2): (91-96). [PMID:21666860] |
| 2. Janero DR, Vadivel SK, Makriyannis A. (2009) Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.. Int Rev Psychiatry, 21 (2): (122-33). [PMID:19367506] |
| 3. Pertwee RG. (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.. Proc Nutr Soc, 73 (1): (96-105). [PMID:24135210] |
| 4. Sałaga M, Sobczak M, Fichna J. (2014) Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.. Eur J Pharm Sci, 52 (173-9). [PMID:24275607] |
| 5. van Esbroeck ACM, Janssen APA, Cognetta 3rd AB, Ogasawara D, Shpak G, van der Kroeg M, Kantae V, Baggelaar MP, de Vrij FMS, Deng H et al.. (2017) Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.. Science, 356 (6342): (1084-1087). [PMID:28596366] |